WO2001034554A1

WO2001034554A1 - Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders

Info

Publication number: WO2001034554A1
Application number: PCT/US2000/029225
Authority: WO
Inventors: L. Wayne Schneider; Daniel A. Gamache; Lori K. Weimer; Timothy L. Kessler; Zhongyou Wei; Terri Pasquine; John M. Yanni; Haresh G. Bhagat
Original assignee: Alcon Universal Ltd.
Priority date: 1999-11-09
Filing date: 2000-10-23
Publication date: 2001-05-17
Also published as: EP1228032B1; HK1045986A1; DE60012774D1; MXPA02004703A; CN1387505A; TWI267375B; AU1340801A; CA2386619A1; ATE272603T1; JP2003513951A; TR200201246T2; DK1228032T3; KR20020050239A; US6353022B1; AR029190A1; PT1228032E; BR0015416A; PL355998A1; HK1045986B; ES2220561T3

Abstract

Compositions containing one or more HETE derivative(s) and an effective concentration of ethanol and methods of use for treating dry eye are disclosed.

Description

Compositions Containing Hydroxyeicosatetraenoic Acid Derivatives and Methods of Use in Treating Dry Eye Disorders

The present invention is directed to improved compositions containing

hydroxyeicosatetraenoic acid derivatives and ethanol and methods for their use in

treating dry eye.

Background of the Invention

Dry eye, also known generically as keratoconjunctivitis sicca, is a common ophthalmological disorder affecting millions of Americans each year. The condition

is particularly widespread among post-menopausal women due to hormonal changes

following the cessation of fertility. Dry eye may afflict an individual with varying

severity. In mild cases, a patient may experience burning, a feeling of dryness, and persistent irritation such as is often caused by small bodies lodging between the eye

lid and the eye surface. In severe cases, vision may be substantially impaired. Other

diseases, such as Sjogren's disease and cicatricial pemphigoid manifest dry eye

complications.

Although it appears that dry eye may result from a number of unrelated

pathogenic causes, all presentations of the complication share a common effect, that is

the breakdown of the pre-ocular tear film, which results in dehydration of the exposed

outer surface and many of the symptoms outlined above (Lemp, Report of the

National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes, The CLAO

Journal, volume 21, number 4, pages 221-231 (1995)). Practitioners have taken several approaches to the treatment of dry eye. One

common approach has been to supplement and stabilize the ocular tear film using

so-called artificial tears instilled throughout the day. Other approaches include the use

of ocular inserts that provide a tear substitute or stimulation of endogenous tear

production.

Examples of the tear substitution approach include the use of buffered,

isotonic saline solutions containing water soluble polymers that render the solutions

more viscous and thus less easily shed by the eye. Tear reconstitution is also

attempted by providing one or more components of the tear film such as

phospholipids and oils. Phospholipid compositions have been shown to be useful in

treating dry eye; see, e.g., McCulley and Shine, Tear film structure and dry eye,

Contactologia, volume 20(4), pages 145-49 (1998); and Shine and McCulley, Keratoconjunctivitis sicca associated with meibomian secretion polar lipid

abnormality, Archives of Ophthalmology, volume 116(7), pages 849-52 (1998).

Examples of phospholipid compositions for the treatment of dry eye are disclosed in

United States Patent Nos. 4,131,651 (Shah et al.), 4,370,325 (Packman), 4,409,205

(Shively), 4,744,980 and 4,883,658 (Holly), 4,914,088 (Glonek), 5,075,104 (Gressel

et al.), 5,278,151 (Korb et al.), 5,294,607 (Glonek et al.), 5,371,108 (Korb et al.) and

5,578,586 (Glonek et al.). U.S. Patent No. 5,174,988 (Mautone et al.) discloses

phospholipid drug delivery systems involving phospholipids, propellants and an active

substance.

United States Patent No. 3,991,759 (Urquhart) discloses the use of ocular

inserts in the treatment of dry eye. Other semi-solid therapy has included the administration of carrageenans (United States Patent No. 5,403,841, Lang) which gel upon contact with naturally occurring tear film.

Another approach involves the provision of lubricating substances in lieu of

artificial tears. For example, United States Patent No. 4,818,537 (Guo) discloses the

use of a lubricating, liposome-based composition, and United States Patent No.

5,800,807 (Hu et al.) discloses compositions containing glycerin and propylene glycol

for treating dry eye.

Aside from the above efforts, which are directed primarily to the alleviation of

symptoms associated with dry eye, methods and compositions directed to treatment of the dry eye condition have also been pursued. For example, United States Patent No.

5,041,434 (Lubkin) discloses the use of sex steroids, such as conjugated estrogens, to

treat dry eye condition in post-menopausal women; United States Patent No.

5,290,572 (MacKeen) discloses the use of finely divided calcium ion compositions to

stimulate pre-ocular tear film production; and United States Patent No. 4,966,773

(Gressel et al.) discloses the use of microfine particles of one or more retinoids for

ocular tissue normalization.

Although these approaches have met with some success, problems in the

treatment of dry eye nevertheless remain. The use of tear substitutes, while

temporarily effective, generally requires repeated application over the course of a

patient's waking hours. It is not uncommon for a patient to have to apply artificial

tear solution ten to twenty times over the course of the day. Such an undertaking is

not only cumbersome and time consuming, but is also potentially very expensive.

Transient symptoms of dry eye associated with refractive surgery have been reported

to last in some cases from six weeks to six months or more following surgery. The use of ocular inserts is also problematic. Aside from cost, they are often unwieldy and uncomfortable. Further, as foreign bodies introduced in the eye, they

can be a source of contamination leading to infections. In situations where the insert

does not itself produce and deliver a tear film, artificial tears must still be delivered on

a regular and frequent basis.

In view of the foregoing, there is a clear need for an effective, convenient

treatment for dry eye that is capable of alleviating symptoms, as well as treating the

underlying physical and physiological deficiencies of dry eye.

Mucins are proteins which are heavily glycosylated with glucosamine-based

moieties. Mucins provide protective and lubricating effects to epithelial cells,

especially those of mucosal membranes. Mucins have been shown to be secreted by

vesicles and discharged on the surface of the conjunctival epithelium of human eyes (Greiner et al., Mucous Secretory Vesicles in Conjunctival Epithelial Cells of Wearers

of Contact Lenses, Archives of Ophthalmology, volume 98, pages 1843-1846 (1980);

and Dilly et al., Surface Changes in the Anaesthetic Conjunctiva in Man, with Special

Reference to the Production of Mucous from a Non-Goblet-Cell Source, British

Journal of Ophthalmology, volume 65, pages 833-842 (1981)). A number of human-

derived mucins which reside in the apical and subapical corneal epithelium have been

discovered and cloned (Watanabe et al., Human Corneal and Conjunctival Epithelia

Produce a Mucin-Like Glycoprotein for the Apical Surface, Investigative

Ophthalmology and Visual Science, volume 36, number 2, pages 337-344 (1995)).

Recently, Watanabe discovered a new mucin which is secreted via the cornea apical

and subapical cells as well as the conjunctival epithelium of the human eye (Watanabe

et al., IOVS, volume 36, number 2, pages 337-344 (1995)). These mucins provide lubrication, and additionally attract and hold moisture and sebaceous material for

lubrication and the corneal refraction of light.

Mucins are also produced and secreted in other parts of the body including

lung airway passages, and more specifically from goblet cells interspersed among

tracheal/bronchial epithelial cells. Certain arachidonic acid metabolites have been

shown to stimulate mucin production in these cells. Yanni reported the increased

secretion of mucosal glycoproteins in rat lung by hydroxyeicosatetraenoic acid

("HETE") derivatives (Yanni et al, Effect of Intravenously Administered Lipoxygenase

Metabolites on Rat Trachael Mucous Gel Layer Thickness, International Archives of

Allergy And Applied Immunology, volume 90, pages 307-309 (1989)). Similarly,

Marom has reported the production of mucosal glycoproteins in human lung by HETE

derivatives (Marom et al., Human Airway Monohydroxy- eicosatetraenoic Acid

Generation and Mucous Release, Journal of Clinical Investigation, volume 72, pages

122-127 (1983)).

Agents claimed for increasing ocular mucin and/or tear production include

vasoactive intestinal polypeptide (Dartt et. al., Vasoactive intestinal peptide-

stimulated glycocongjugate secretion from conjunctival goblet cell, Experimental Eye

Research, volume 63, pages 27-34, (1996)), gefarnate (Nakmura et. al., Gefarnate

stimulates secretion of mucin-like glycoproteins by corneal epithelium in vitro and

protects corneal epithelium from dessication in vivo, Experimental Eye Research,

volume 65, pages 569-574 (1997)), liposomes (U.S. Patent No. 4,818,537), androgens

(U.S. Patent No. 5,620,921), melanocycte stimulating hormones (U.S. Patent No.

4,868,154), phosphodiesterase inhibitors (U.S. Patent No. 4,753,945), and retinoids

(U.S. Patent No. 5,455,265). However, many of these compounds or treatments suffer from a lack of specificity, efficacy and potency and none of these agents have been marketed so far as therapeutically useful products to treat dry eye and related ocular

surface diseases.

U.S. Patent No. 5,696,166 (Yanni et al.) discloses compositions containing

HETEs and methods of use for treating dry eye. Yanni et al. discovered that

compositions comprising HETEs increase ocular mucin secretion when administered

to a patient and are thus useful in treating dry eye. The inventors of the present

invention have improved on such compositions and methods by inventing HETE

derivative compositions having improved efficacy relative to those disclosed in the 5,696,166 patent.

Summary of the Invention

The present invention is directed to compositions and methods for the

treatment of dry eye and other disorders requiring the wetting of the eye, including

symptoms of dry eye associated with refractive surgery such as LASIK surgery. More

specifically, the present invention discloses improved compositions containing HETE

derivatives and methods for treating dry eye-type diseases and disorders. The HETE

containing compositions comprise one or more HETE derivatives and an effective

concentration of ethanol to improve the efficacy of the HETE derivative(s) in vivo.

The compositions are preferably administered topically to the eye.

In a preferred embodiment, HETE derivatives are formulated with an artificial

tear component or phospholipid in order to provide compositions that give both

immediate and long term relief from dry eye or other disorders requiring the wetting

of the eye. Description of the Drawings

FIG. 1 is a graph illustrating the improved dry eye efficacy of a composition

comprising 15(S)-HETE and ethanol versus an analogous composition containing no

ethanol in an in vivo dry eye model.

FIG. 2 is a graph illustrating the improved dry eye efficacy of compositions

comprising 15(S)-HETE and varying concentrations of ethanol versus a composition

containing no 15(S)-HETE in an in vivo dry eye model.

Detailed Description of the Invention

It has now been discovered that HETE derivative-containing compositions comprising an effective amount of ethanol are more efficacious for treating dry eye-

type disorders than corresponding compositions containing no ethanol. As used

herein, the term "HETE derivative" refers to any hydroxyeicosatetraenoic acid-like derivative that stimulates ocular mucin production and/or secretion following topical

ocular application, and are of the following formulas (I), (II) or (III):

wherein:

X is OR or NHR;

R is H, substituted or unsubstituted alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl, arylalkyl, wherein the substitution is made with a moiety selected from the group consisting of: alkyl, halogen, hydroxy and functionally modified hydroxy; and

Y is

- ^c— r -;C—

H OR" R"0 H .

wherein R ' ' is H or OR ' ' is a functionally modified hydroxy group.

Included within the scope of the present invention are the individual

enantiomers of the compounds of the present invention, as well as their racemic and non-racemic mixtures. The individual enantiomers can be enantioselectively

synthesized from the appropriate enantiomerically pure or enriched starting material

by means such as those described below. Alternatively, they may be

enantioselectively synthesized from racemic/non-racemic or achiral starting materials.

(Asymmetric Synthesis; J. D. Morrison and J. W. Scott, Eds.; Academic Press

Publishers: New York, 1983-1985, volumes 1-5; Principles of Asymmetric Synthesis;

R. E. Gawley and J. Aube, Eds.; Elsevier Publishers: Amsterdam, 1996). They may

also be isolated from racemic and non-racemic mixtures by a number of known

methods, e.g. by purification of a sample by chiral HPLC (A Practical Guide to Chiral

Separations by HPLC; G. Subramanian, Ed.; VCH Publishers: New York, 1994;

Chiral Separations by HPLC; A.M. Krstulovic, Ed.; Ellis Horwood Ltd. Publishers, 1989), or by enantioselective hydrolysis of a carboxylic acid ester sample by an

enzyme (Ohno, M.; Otsuka, M. Organic Reactions, volume 37, page 1 (1989)). Those

skilled in the art will appreciate that racemic and non-racemic mixtures may be

obtained by several means, including without limitation, nonenantioselective

synthesis, partial resolution, or even mixing samples having different enantiomeric

ratios. Departures may be made from such details within the scope of the

accompanying claims without departing from the principles of the invention and

without sacrificing its advantages. Also included within the scope of the present

invention are the individual isomers substantially free of their respective enantiomers.

The term "free hydroxy group" means an OH. The term "functionally modified

hydroxy group" means an OH which has been functionalized to form: an ether, in which an alkyl, aryl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, alkynyl, or heteroaryl group is substituted for the hydrogen; an

ester, in which an acyl group is substituted for the hydrogen; a carbamate, in which an aminocarbonyl group is substituted for the hydrogen; or a carbonate, in which an

aryloxy-, heteroaryloxy-, alkoxy-, cycloalkoxy-, heterocycloalkoxy-, alkenyloxy-, cycloalkenyloxy-, heterocycloalkenyloxy-, or alkynyloxy-carbonyl group is substituted

for the hydrogen. Preferred moieties include OH, OCH₂C(O)CH₃, OCH₂C(O)C₂H₅,

OCH₃, OCH₂CH₃, OC(O)CH₃, and OC(O)C₂H₅.

The term "acyl" represents a group that is linked by a carbon atom that has a

double bond to an oxygen atom and a single bond to another carbon atom.

The term "alkyl" includes straight or branched chain aliphatic hydrocarbon

groups that are saturated and have 1 to 15 carbon atoms. The alkyl groups may be

substituted with other groups, such as halogen, hydroxyl or alkoxy. Preferred straight or branched alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and t-butyl.

The term "cycloalkyl" includes straight or branched chain, saturated or

unsaturated aliphatic hydrocarbon groups which connect to form one or more rings,

which can be fused or isolated. The rings may be substituted with other groups, such

as halogen, hydroxyl, alkoxy, or lower alkyl. Preferred cycloalkyl groups include

cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term "alkenyl" includes straight or branched chain hydrocarbon groups

having 1 to 15 carbon atoms with at least one carbon-carbon double bond. The chain

hydrogens may be substituted with other groups, such as halogen. Preferred straight or

branched alkenyl groups include, allyl, 1-butenyl, 1 -methyl-2-propenyl and 4-

pentenyl.

The term "cycloalkenyl" includes straight or branched chain, saturated or

unsaturated aliphatic hydrocarbon groups which connect to form one or more non-

aromatic rings containing a carbon-carbon double bond, which can be fused or isolated. The rings may be substituted with other groups, such as halogen, hydroxyl,

alkoxy, or lower alkyl. Preferred cycloalkenyl groups include cyclopentenyl and

cyclohexenyl.

The term "alkoxy" represents an alkyl group attached through an oxygen

linkage.

The term "carbonyl group" represents a carbon atom double bonded to an

oxygen atom, wherein the carbon atom has two free valencies.

The term "alkoxycarbonyl" represents an alkoxy group bonded from its

oxygen atom to the carbon of a carbonyl group, the carbonyl group itself being bonded

to another atom through its carbon atom. The term "aminocarbonyl" represents an amino group bonded from its

nitrogen atom to the carbon atom of a carbonyl group, the carbonyl group itself being

bonded to another atom through its carbon atom.

The term "lower alkyl" represents alkyl groups containing one to six carbons

(C C₆).

The term "halogen" represents fluoro, chloro, bromo, or iodo.

The term "aryl" refers to carbon-based rings which are aromatic. The rings may be isolated, such as phenyl, or fused, such as naphthyl. The ring hydrogens may

be substituted with other groups, such as lower alkyl, or halogen.

The term "heteroaryl" refers to aromatic hydrocarbon rings which contain at

least one heteroatom such as O, S, or N in the ring. Heteroaryl rings may be isolated, with 5 to 6 ring atoms, or fused, with 8 to 10 atoms. The heteroaryl ring(s) hydrogens

or heteroatoms with open valency may be substituted with other groups, such as lower

alkyl or halogen. Examples of heteroaryl groups include imidazole, pyridine, indole, quinoline, furan, thiophene, pyrrole, tetrahydroquinoline, dihydrobenzofuran, and

dihydrobenzindole.

The term "heterocycloalkyl" refers to a cycloalkyl ring containing at least one

heteroatom, such as N, O, or S, within the ring structure. Examples of

heterocycloalkyl rings include tetrahydropyran, pyrrolidine, piperidine, piperazine,

tetrahydrothiophene, and morpholine.

The term "heterocycloalkenyl" refers to a cycloalkenyl ring containing at least

one heteroatom, such as N, O, or S, within the ring structure. Examples of

heterocycloalkenyl rings include dihydropyran, pyrroline, and pyridone. The HETE derivatives of the present invention are typically derived from

arachidonic acid. Certain of the HETE derivatives are known in the art and have been

isolated ex vivo as well as prepared biosynthetically and synthetically. Some HETE

derivatives are made endogenously by the action of lipoxygenases or other enzymes

and subsequent reductions through the actions of endogenous peroxidases. Several

lipoxygenases are known to exist and are named for the carbon position which they

oxidize. Such enzymes include 5-lipoxygenase, 12-lipoxygenase and 15-

lipoxygenase. Other enzymes such as cytochrome P-450 have been observed to

catalyze "R-type" HETE oxidized products. Each lipoxygenase catalyzes the addition of a hydroperoxy group at the respective carbon. After hydroperoxidation, which

forms such molecules as 5-hydroperoxyeicosatetraenoic acid ("5-HPETE"), 12- HPETE and 15-HPETE, the arachidonate derivatives are reduced to the resulting

alcohol by various peroxidases. The resulting molecules include 5-HETE, 12-HETE

and 15-HETE.

HETES can be obtained biosynthetically, by in vitro synthesis. Such methods

have involved the use of the respective lipoxygenase, O₂, arachidonic acid and a

suitable reducing agent (See, Graff et al., Activation of Soluble Splenic Cell Guanylate

Cyclase by Prostaglandin Endoperoxides and Fatty Acid Hydroper oxides, Journal of

Biological Chemistry, volume 253, pages 7662-7676 (1978) and Graff, Preparation of

15-L-Hydroperoxy-5, 8,11,13- eicosatetraenoic acid (15-HPETE), Methods in

Enzymology, volume 86, pages 386-392 (1982)). HETEs may also be synthesized by

organic synthetic routes such as described in Corey et al, 12-Hydroxy-5,8,14-(Z)-10-

(E)-eicosatetraenoic Acid (12-HETE), The Logic of Chemical Synthesis, John Wiley

and Sons, sections 12.9 and 12.11 (1989). Finally, HETEs are commercially available from various sources including Sigma Chemical Co. (St. Louis, Missouri) and

Cayman Chemical (Ann Arbor, Michigan). The level of peroxy compounds in the

HETE derivative raw materials that are used to prepare the pharmaceutical

formulations of the present invention may have an impact on the HETE derivative's

biological activity. Although the precise relationship has not been defined, it is

preferable to use HETE derivative raw material supplies containing peroxy

compounds at levels no greater than about 0.3 ppm. Methods for determining peroxy

levels are known in the art (e.g., European Pharmacopoeia 1997 3^rd Ed., Method 2.5.5 - Peroxide Value).

It is believed that the use of ethanolic stock solutions of the HETE derivatives

in the preparation of the compositions limits the presence of degradation products in the final compositions.

Preferred compounds of the present invention include:

5,8,10,14-Eicosatetraenoic acid, 12-hydroxy-, [12S-(5Z,8Z,10E,14Z)]- ("12(5)- HETE");

5,8,11,13-Eicosatetraenoic acid, 15-hydroxy-, [15S-(5Z,8Z,11Z,13E)]- ("15(S)- HETE");

The compositions of the present invention comprise one or more HETE

derivatives in an amount effective to secrete mucin in the eye and thus eliminate or

improve dry eye conditions when administered to the eye. As used herein, the term

"pharmaceutically effective amount" refers to an amount of one or more HETE

derivatives which improves the dry eye condition in a mammal. Generally, the HETE

derivatives will be contained in the compositions in a concentration range of from

0.00001 to about 1 per cent weight/volume ("% w/v"), and preferably 0.00001 to

about 0.01% w/v. Compositions comprising 15(S)-HETE in a concentration of from about 0.00001-0.0001% w/v are most preferred.

As stated above, the compositions of the present invention also comprise an

effective concentration of ethanol. The inventors of the present invention

unexpectedly found that the presence of ethanol in the HETE derivative compositions

enhanced the biological efficacy of the HETE derivatives when administered to the

eye. As used herein with regard to ethanol, an "amount sufficient to enhance the

efficacy of the HETE derivative(s)" refers to a concentration of ethanol that enhances

the biological efficacy of the HETE derivative compositions when dosed topically to

the eye. In general, the concentration of ethanol necessary for the enhancement of the

HETE derivatives is believed to be somewhat proportional to the concentration of the

HETE derivative(s) administered. If a relatively high concentration of HETE

derivative, e.g., above 0.01% w/v, is administered, the concentration of ethanol in such compositions may be proportionally less than analogous compositions containing

lower concentrations of HETE derivatives. In general, however, the ethanol

concentration contained in the compositions of the present invention will range from

about 0.001-2% w/v. Compositions containing HETE derivative concentrations of

about 0.00001-0.01% w/v preferably will contain ethanol in a concentration of about

0.005-0.20% w/v, and most preferably, about 0.02-0.10% w/v.

The HETE derivative compositions will be formulated as solutions,

suspensions and other dosage forms for topical administration. Aqueous solutions are

generally preferred, based on ease of formulation, biological compatibility (especially in view of the malady to be treated, i.e., dry eye-type disorders), as well as a patient's

ability to easily administer such compositions by means of instilling one to two drops

of the solutions in the affected eyes. However, the HETE derivative compositions

may also be suspensions, viscous or semi-viscous gels, or other types of solid or semi- solid compositions. Suspensions may be preferred for HETE derivatives which are

less soluble in water.

Preferably, the compositions of the present invention will also contain a

surfactant. Various surfactants useful in topical ophthalmic formulations may be

employed. The surfactant(s) may provide additional chemical stabilization of the

HETE derivatives and may further provide for the physical stability of the compounds.

In other words, the surfactants may aid in preventing chemical degradation of the

HETE derivatives and also prevent the compounds from binding to the containers in

which their compositions are packaged. As used herein, "an effective concentration of

surfactant(s)" refers to a concentration that enhances the chemical and physical

stability of HETE derivatives. Examples of surfactants include, but are not limited to: Cremophor^® EL, polyoxyl 20 ceto stearyl ether, polyoxyl 40 hydrogenated castor oil,

polyoxyl 23 lauryl ether and poloxamer 407 may be used in the compositions. A

preferred surfactant is polyoxyl 40 stearate. The concentration of surfactant will vary, will vary, depending on the concentration of the HETE derivative(s) and ethanol

included in the formulation. In general, however, the surfactant(s) concentration will

be about 0.001 to 2.0% w/v. Preferred compositions of the present invention will

contain about 0.1% w/v of polyoxyl 40 stearate.

The pharmaceutical compositions of the present invention may also include

various other ingredients, such as tonicity agents, buffers, preservatives, co-solvents

and antioxidants.

Various tonicity agents may be employed to adjust the tonicity of the

pharmaceutical composition, preferably to that of natural tears. For example, sodium

chloride, potassium chloride, magnesium chloride, calcium chloride and or mannitol

may be added to the composition to approximate physiological tonicity. Such an amount of tonicity agent will vary, depending on the particular agent to be added. In

general, however, the compositions will have a tonicity agent concentration of about

0.1-1.5% w/v. Preferred pharmaceutical compositions will contain about 0.75% w/v

of sodium chloride.

An appropriate buffer system (e.g., sodium phosphate, sodium acetate, sodium

citrate, sodium borate or boric acid) may be added to prevent pH drift under storage

conditions. The particular concentration will vary, depending on the agent employed.

In general, such a concentration will range from about 0.02 to 2.0% w/v. Preferred

compositions will contain about 0.25% w/v of boric acid. Topical ophthalmic products are typically packaged in multidose form.

Preservatives are thus required to prevent microbial contamination during use.

Suitable preservatives include: benzalkonium chloride, chlorobutanol,

benzododecinium bromide, methyl paraben, propyl paraben, phenylethyl alcohol,

edetate disodium, sorbic acid, polyquaternium-1, or other agents known to those

skilled in the art. Such preservatives are typically employed at a level of from 0.001

to 1.0% w/v. Unit dose compositions of the present invention will be sterile, but

typically unpreserved. Such compositions, therefore, generally will not contain

preservatives. Antioxidants may be added to compositions of the present invention to protect

the HETE salts from oxidation during storage. Examples of such antioxidants

include, but are not limited to, vitamin E and analogs thereof, ascorbic acid and

derivatives, and butylated hydroxyanisole (BHA).

In a preferred embodiment, the pharmaceutical compositions of the present

invention include one or more artificial tear or phospholipid components to provide

immediate relief while the HETE salts stimulate natural tear production. In this

embodiment, the compositions of the present invention provide a two-pronged

approach to the treatment of dry eye. The artificial tear or phospholipid component of

the compositions provides immediate, temporary relief of dry eye by lubricating and

wetting the eye, and the HETE derivative component of the compositions provides

pharmaceutical therapy by stimulating the rebuilding of the patient's natural tears

through the stimulation of ocular secretion of mucin. An advantage of compositions

according to this embodiment, which provide both immediate, temporary relief as well

as long-term dry eye relief, is that they do not need to be administered at high frequency typical of non-therapeutic phospholipid compositions. instead, the compositions of the present invention may be administered as little as one to two

times per day to as much as only about eight to ten times a day, depending on the

severity of the dry eye condition.

Another advantage of the compositions containing a HETE salt and an

artificial tear or phospholipid component is that the compositions provide ease of use

over separate, single therapy compositions. In order for a patient to even attempt to gain both short-term and long-term dry eye relief, the patient would need to juggle two

separate composition dosing regimens. With such a two composition regimen, the

user is encumbered with handling two separate compositions and following the

different dosing regimens. Additionally, due to possible overlap of administration, a user of two separate systems may inadvertently overdose one composition or the

other, or effectively over-dilute one composition or the other by concomitant dosing

of the two compositions. The present invention would solve such problems by

providing a single, multi-therapeutic composition for the treatment of dry eye-type

diseases and disorders.

As used herein, "one or more artificial tear or phospholipid components" refers

to those components that: (i) lubricate, "wet," approximate the consistency of

endogenous tears, or otherwise provide temporary relief of the dry eye symptoms and

conditions upon ocular administration; (ii) are safe; and (iii) provide an appropriate

delivery vehicle for the topical administration of an effective amount of one or more

HETE derivatives. As used herein, "an effective amount of one or more artificial tear or

phospholipid components" refers to that amount which lubricates, "wets,"

approximates the consistency of endogenous tears, or otherwise provides temporary relief of the dry eye symptoms and conditions upon ocular administration. In general,

the concentration of the artificial tear or phospholipid components in the compositions

of the present invention will range from about 0.01 to about 1.0% w/v (phospholipid

component) or 2.0% w/v (non-phospholipid component). Preferred amounts will

range from about 0.05 to about 0.1% w/v (phospholipid components) and 0.1 - 0.5%

w/v (non-phospholipid component).

The phospholipid components useful in the compositions of the present

invention are any natural or synthetic phospholipid compounds comprising a glycerol-

phosphoric acid ester or sphingosine backbone. Examples of phospholipids of the

present invention are of formula (IV):

(IV)

wherein, X²¹ and X²² are the same or different and are O, NH(C=O), O(C=O), or a direct bond;

R²² is H or CH=CH(CH₂)₁₂CH₃;

X²¹-R^] is OH, or R¹ is Cι_2-26 substituted or unsubstituted alkyl or alkenyl;

R is Ci_{2- 6} substituted or unsubstituted alkyl or alkenyl; and

R³ is OH, OCH₂CH(NH₃ ⁺)COO^", OCH₂CH₂NH₃ ⁺, OCH₂CH₂N⁺(CH₃)₃,

OCH₂CH(OH)CH₂OH and O-inositol.

The phospholipids may be present as racemic or non-racemic compounds.

Preferred phospholipids are those wherein X²¹-R¹ and/or X²²-R² comprise fatty acid

esters or amides. Natural fatty acids are saturated, monounsaturated or polyunsaturated. Examples of fatty acid residues include, but are not limited to,

laurate, myristate, palmitate, palmitoleate, stearate, oleate, linoleate, linolenate,

eicosanoate, docosanoate and lignocerate. Preferred phospholipid types are the

phosphatidylethanolamines, phosphatidylcholines, phosphatidylserines,

phospatidylinositols and sphingomyelins. Examples of specific phospholipids

include: 1,2-dipalmitoyl phosphatidyl choline ("DPPC") 1 ,2-dipalmityl phosphatidyl

glycerol ("DPPG"), N-stearyl sphingomyelin, N-palmityl sphingomyelin, N-oleyl

sphingomyelin, 1,2-distearoyl phosphatidyl ethanolamine ("DSPE"), 1,2-distearoyl

phosphatidyl inositol ("DSPI"), l-stearoyl-2-palmitoyl phosphatidyl ethanolamine

("SPPE"), l-stearoyl-2-palmitoyl phosphatidyl choline ("SPPC"), 1,2-dipalmitoyl

phosphatidyl ethanolamine ("DPPE"), 1,2-dioleoyl phophatidyl ethanolamine

("DOPE"), 1,2-dioleoyl phophatidyl serine ("DOPS"), and 1,2-dipalmitoyl phosphatidyl serine ("DPPS"). The most preferred phospholipid carriers are the

phosphatidylethanolamines and sphingomyelins. Phospholipids are available from a variety of natural sources and may be synthesized by methods known in the art; see,

for example, Tsai et. al., Biochemistry, volume 27, page 4619 (1988); and Dennis et.

al., Biochemistry, volume 32, page 10185 (1993).

Various non-phospholipid artificial tear components are known and are useful

in providing lubrication, "wetting," approximation of the consistency of endogenous

tears, or otherwise providing temporary relief of the dry eye symptoms and conditions

upon ocular administration. Such compounds may enhance the viscosity of the

composition, and include, but are not limited to: monomeric polyols, such as, glycerol,

propylene glycol, ethylene glycol; polymeric polyols, such as, polyethylene glycol,

hydroxypropylmethyl cellulose ("HPMC"), carboxy methylcellulose sodium, and hydroxy propylcellulose ("HPC"); hyaluronic acid; chondroitin sulfate; dextrans, such

as, dextran 70; water soluble proteins, such as gelatin; and vinyl polymers, such as,

polyvinyl alcohol, polyvinylpyrrolidone, povidone and carbomers, such as, carbomer

934P, carbomer 941, carbomer 940, carbomer 974P. In general, the compositions will

exhibit a viscosity of 1 to 400 centipoises ("cps"). Preferred compositions will exhibit

a viscosity of about 25 cps.

The compositions of the present invention are intended for administration to a

mammal suffering from dry eye or symptoms of dry eye. Preferably, the HETE

derivatives of the present invention will be administered topically. In general, the

doses used for the above described purposes will vary, but will be in an effective

amount to alleviate the symptoms of dry eye, increase mucin production in the eye and thus eliminate or improve dry eye conditions. As used herein, the term

"therapeutically effective amount" refers to an amount of a composition of the present invention that, when administered to a mammal, improves the dry eye condition of the

mammal. Generally, 1-2 drops of the compositions of the present invention will be

administered 1-10 times per day, depending on various factors such as the

concentration of the HETE derivative(s) in the compositions, the potency of the

particular HETE derivatives, as well as the severity of the dry eye disease or disorder

to be treated. Preferably, 1-2 drops of the compositions will be administered 1-4

times per day.

As used herein, the term "pharmaceutically acceptable carrier" refers to any

formulation which is safe, and provides the appropriate delivery of an effective amount

of at least one HETE derivative of the present invention and an effective amount of

ethanol. The following Examples 1- describe preferred compositions of the present

invention. Variations of the exemplified compositions may also be prepared, e.g.,

substituting a HETE derivative of formula (I) or (II) for the compound of formula

(HI), modifying the concentration of the HETE derivative to between about 0.00001 to

1% w/v, varying the concentrations of the other components present, and modifying the

pH (e.g., between about 6-8).

Example 1

The above composition is prepared by the following method. The batch

quantities of polyoxyl 40 stearate, boric acid, sodium chloride, disodium edetate, and

polyquaternium-1 are weighed and dissolved by stirring in 90% of the batch quantity of

purified water. The pH is adjusted to 7.5 ± 0.1 with NaOH and/or HCl. Under yellow

light or reduced lighting, the batch quantity of the chosen compound of formula (HI) as a

stock solution in ethanol and the additional quantity of ethanol necessary for the batch

are measured and added. Purified water is added to q.s. to 100%. The mixture is stirred for five minutes to homogenize and then filtered through a sterilizing filter membrane

into a sterile recipient.

Preferably, the above process is performed using glass, plastic or other non-

metallic containers or containers lined with such materials.

Example 2

The above formulation may be made by a method similar to the method described in

Example 1.

Example 3

Example 1.

Example 4

A composition of the present invention (Example 1, with the compound of

formula (HI) being 15(S)-HETE) was compared to an analogous composition without

ethanol, an analogous composition without 15(S)-HETE, and analogous compositions

with approximately one-half, one-tenth, and twice the amount of ethanol, respectively,

in an in vivo desiccation model of dry eye.

Briefly, the assay was performed by first anesthetizing the animals with ketamine/xylazine/glycopyrrolate. The O.S. eye was lubricated with DuraTears® and

remained taped shut throughout the experiment. The O.D. eye was then dosed with

50μL of test composition (Example 1) or 50 μL of the same composition without

ethanol and the eye taped shut for 10 minutes. The tape was then removed, the eyelids

opened and a speculum was inserted into the eye. The eye was held open with the

speculum for a period of 4 hours. During this time, the animals were monitored every

15 minutes and supplemental injections of ketamine/xylazine (at half the initial

dose/injection) were administered as needed to maintain anesthesia. At the end of the

4-hour period, 2 sutures were placed in the upper eyelid and 1 suture was placed in the

lower eyelid. A corneal/conjunctival cup was formed by using the sutures to lift the

eyelids upward and the sutures taped to a stand. lmL methylene blue (1% solution in

water) was added to the conjunctival cup and the cornea was stained with the solution

for 5 minutes. The eye was then washed with 200mL of a balanced salt solution. Corneal thickness was determined by non-invasive pachymetry. Three readings were taken for each animal. Corneal staining score was obtained by visualizing the cornea with a slit-lamp and determining the percentage of the cornea that was stained with

methylene blue. A photograph was taken using the slit-lamp machine. The rabbit was

then euthanized immediately by intravenous injection of Sleepaway® solution and the

eye was excised. The cornea was isolated and an 8mm punch of the central cornea

collected. This corneal punch was placed in a small glass vial containing 2mL

acetone/saturated sodium sulfate (7:3, vol/vol). Absorbance of the extracted solution

was measured at 660nm with a spectrophotometer.

The naive control animals were anesthetized with

ketamine/xylazine/glycopyrrolate and the O.S. eye lubricated and taped shut. Sutures

were immediately placed in the O.D. eyelids. The corneal cup was formed and the

cornea was stained with methylene blue, washed with a balanced salt solution and collected, as described above. The data were converted to "percent protection" by

subtracting from 1 , the quotient of the test sample absorbances divided by the average

of control sample absorbance, and multiplying by 100. The results are contained in Table 1 and illustrated in FIGS. 1 and 2:

Table 1

* p< 0.05 versus control. Note: 1 μM corresponds to 0.000034% w/v

The above results demonstrate the effects of ethanol in combination with a

s HETE derivative on the protection against comeal injury induced by dry eye

conditions.

The following Examples 5-10 (phospholipid compositions) and 11-19 (non- phospholipid artificial tear component compositions) illustrate specific compositions

of the present invention.

Example 5

The above composition is prepared by the following method. The batch

quantities of DPPC, DPPG, sodium chloride, potassium chloride, dibasic sodium phosphate, disodium EDTA, polyquatemium-1, are weighed and dissolved by stirring in

90% of the batch quantity of purified water. The pH is adjusted to 7.5 ± 0.1 with NaOH

and/or HCl. Under yellow light or reduced lighting, the batch quantity of the chosen

compound of formula (III) as a stock solution in ethanol and the additional quantity of

ethanol necessary for the batch are measured and added. Purified water is added to q.s.

to 100%. The mixture is stirred for five minutes to homogenize and then filtered

through a sterilizing filter membrane into a sterile recipient.

Preferably, the above process is performed using glass, plastic or other non-

metallic containers or containers lined with such materials. The formulations of Examples 6 - 10 may be made by a method similar to that described in Example 5.

Example 6

Example 7

Example 8

Example 9

Example 10

Example 11

The above composition is prepared by the following method. The batch

quantities of HPMC, dextran 70, benzalkonium chloride, sodium chloride, potassium

chloride and disodium EDTA are weighed and dissolved by stirring in 90% of the batch quantity of purified water. The pH is adjusted to 7.5 ± 0.1 with NaOH and/or HCl.

Under yellow light or reduced lighting, the batch quantity of the chosen compound of

formula (HI) as a stock solution in ethanol and the additional quantity of ethanol

necessary for the batch are measured and added. Purified water is added to q.s. to 100%.

The mixture is stirred for five minutes to homogenize and then filtered through a

sterilizing filter membrane into a sterile recipient.

Preferably, the above process is performed using glass, plastic or other non-

metallic containers or containers lined with such materials.

The formulations of Examples 12 - 19 may be made by a method similar to

that described in Example 11.

Example 12

Example 13

Example 14

Example 15

Example 16

Example 17

Example 18

Example 19

The invention in its broader aspects is not limited to the specific details shown

and described above. Departures may be made from such details within the scope of the

accompanying claims without departing from the principles of the invention and without

sacrificing its advantages.

Claims

What is claimed is:

1. A composition for the treatment of dry eye and other disorders requiring the

wetting of the eye comprising a pharmaceutically acceptable carrier, a

pharmaceutically effective amount of one or more HETE derivatives according to

formulas (I), (II) or (III), and ethanol in an amount sufficient to enhance the efficacy of

the HETE derivative(s):

wherein:

X is OR or NHR;

Y is

wherein R ' ' is H or OR ' ^■ is a functionally modified hydroxy group.

2. The composition of Claim 1, wherein the HETE derivative is selected from the group consisting of: 5(S)-HETE, 5(R)-HETE, 12(S)-HETE, 12(_?)-HETE, 15(S)-

HETE, 15(_-)-HETE and racemic and non-racemic mixtures thereof.

s 3. The composition of Claim 1, wherein the HETE derivative is 15(S)-HETE.

4. The composition of Claim 3, wherein the HETE derivative is contained in the

composition in a concentration of between 0.00001 to 0.01% w/v.

o

5. The composition of Claim 1, wherein the composition further comprises a

surfactant.

6. The composition of Claim 1, wherein the ethanol concentration is between 0.001-2% w/v.

5

7. The composition of Claim 4, wherein the ethanol concentration is between

0.005-0.20% w/v.

8. The composition of Claim 1 further comprising one or more artificial tear or

0 phospholipid components.

9. The composition of Claim 8 wherein the composition comprises a

phospholipid selected from the group consisting of are selected from the group consisting of phosphatidylethanolamines, phosphatidylchohnes, phosphatidylserines, phospatidylinositols and sphingomyelins.

10. The composition of Claim 8 wherein the composition comprises a

s phospholipid of the formula:

(IV)

R²² is H or CH=CH(CH₂)ι₂CH₃;

X²¹-R' is OH, or R¹ is Cι_2-2β substituted or unsubstituted alkyl or alkenyl;

R² is C]_2-26 substituted or unsubstituted alkyl or alkenyl; and

R³ is OH, OCH₂CH(NH₃ ⁺)COO\ OCH₂CH₂NH₃ ⁺, OCH₂CH₂N⁺(CH₃)₃,

OCH₂CH(OH)CH₂OH and O-inositol.

11. The composition of Claim 10, wherein the phospholipid is selected from the

group consisting of: DPPC, DPPG, DSPI, SPPC, DPPE, DOPS, DSPE, SPPE, DOPE,

DPPS, N-stearyl sphingomyelin, N-palmityl sphingomyelin and N-oleyl sphingomyelin.

0 12. The composition of Claim 8 wherein the composition comprises an artificial

tear component selected from the group consisting of monomeric polyols; polymeric

polyols; hyaluronic acid; chondroitin sulfate; dextrans; water-soluble proteins; and

vinyl polymers.

13. The composition of Claim 12 wherein the artificial tear component is selected

from the group consisting of glycerol; propylene glycol; ethylene glycol; polyethylene

glycol; hydroxypropylmethyl cellulose; carboxy methylcellulose sodium; hydroxy

propylcellulose; hyaluronic acid; chondroitin sulfate; dextran 70; gelatin; polyvinyl

alcohol; polyvinylpyrrolidone; povidone; carbomer 934P; carbomer 941; carbomer

940; and carbomer 974P.

14. The composition of Claim 1, wherein the composition further comprises one

or more ingredients selected from the group consisting of surfactants, tonicity agents,

buffers, preservatives, co-solvents and anti-oxidants.

15. A method for the treatment of dry eye and other disorders requiring the wetting of the eye comprising administering to a mammal a composition comprising a

pharmaceutically effective amount of one or more HETE derivatives according to

formulas (I), (II) or (HI), and ethanol in an amount sufficient to enhance the efficacy of

the HETE derivative(s):

wherein:

X is OR or NHR;

Y is

-;^c— or - ^C— hT OR" R"0 H .

wherein R ' ' is H or OR ' ' is a functionally modified hydroxy group.

16. The method of Claim 15, wherein the HETE derivative is selected from the

group consisting of: 5(S)-HETE, 5(R)-HETE, 12(S)-HETE, 12(R)-HETE, 15(5)- HETE, 15(R)- HETE and racemic and non-racemic mixtures thereof.

17. The method of Claim 16, wherein the HETE derivative is 15(S)-HETE.

18. The method of Claim 15, wherein the HETE derivative is contained in the

composition in a concentration of between 0.00001 to 0.01% w/v.

19. The method of Claim 15, wherein the composition further comprises a

surfactant.

20. The method of Claim 15, wherein the ethanol concentration in the

composition is between 0.001-2% w/v.

21. The method of Claim 20, wherein the ethanol concentration in the composition is between 0.005-0.20% w/v.

s 22. The method of Claim 15 wherein the dry eye and other disorders requiring

wetting of the eye is symptoms of dry eye associated with refractive surgery.